Spots Global Cancer Trial Database for stage ii melanoma
Every month we try and update this database with for stage ii melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy | NCT00897520 | Melanoma (Skin) | recombinant int... proteomic profi... immunoenzyme te... laboratory biom... | - 120 Years | Eastern Cooperative Oncology Group | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma | NCT00003641 | Melanoma (Skin) | interferon alfa... observation | 18 Years - | Eastern Cooperative Oncology Group | |
| Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma | NCT00002892 | Melanoma (Skin) | recombinant int... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma | NCT01018004 | Melanoma (Skin) | follow-up care questionnaire a... quality-of-life... | 18 Years - 85 Years | National Cancer Institute (NCI) | |
| Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma | NCT00049010 | Melanoma (Skin) | comparative gen... cytogenetic ana... fluorescence in... immunohistochem... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | NCT00060333 | Recurrent Melan... | radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vaccine Therapy in Treating Patients With Primary Stage II Melanoma | NCT00005052 | Melanoma (Skin) | GM2-KLH vaccine QS21 adjuvant therap... | 18 Years - 80 Years | National Cancer Institute (NCI) | |
| Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer | NCT00436410 | Adrenocortical ... Breast Cancer Colorectal Canc... Gastrointestina... Kidney Cancer Liver Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Sarcoma | colloidal gold-... electron micros... pharmacological... conventional su... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma | NCT01018004 | Melanoma (Skin) | follow-up care questionnaire a... quality-of-life... | 18 Years - 85 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118274 | Melanoma (Skin) | incomplete Freu... melanoma helper... multi-epitope m... tetanus toxoid ... cyclophosphamid... | 18 Years - 120 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Melanoma | NCT00020358 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... tyrosinase pept... | 16 Years - | National Cancer Institute (NCI) | |
| Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members | NCT00346008 | Melanoma (Skin) | mutation analys... high performanc... laboratory biom... questionnaire a... | - | National Cancer Institute (NCI) | |
| Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | NCT00004196 | Melanoma (Skin) | recombinant int... lymphangiograph... Observation | 18 Years - 70 Years | University of Alabama at Birmingham | |
| Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members | NCT00346008 | Melanoma (Skin) | mutation analys... high performanc... laboratory biom... questionnaire a... | - | National Cancer Institute (NCI) | |
| Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma | NCT01018004 | Melanoma (Skin) | follow-up care questionnaire a... quality-of-life... | 18 Years - 85 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00104845 | Melanoma (Skin) | human gp100 pla... mouse gp100 pla... | - | Memorial Sloan Kettering Cancer Center | |
| Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | NCT00060333 | Recurrent Melan... | radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Boron Neutron Capture Therapy in Treating Patients With Melanoma | NCT00059800 | Melanoma (Skin) | boron neutron c... | 18 Years - | National Cancer Institute (NCI) | |
| Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis | NCT00004196 | Melanoma (Skin) | recombinant int... lymphangiograph... Observation | 18 Years - 70 Years | University of Alabama at Birmingham | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery | NCT00470379 | Melanoma (Skin) | resiquimod | 18 Years - | Mayo Clinic | |
| Lovastatin in Treating Patients At High Risk of Melanoma | NCT00462280 | Precancerous Co... Stage 0 Melanom... Stage I Melanom... Stage II Melano... | lovastatin placebo biopsy laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | NCT00470015 | Melanoma (Skin) | MART-1 antigen IL-2 gp100 antigen GM-CSF MART-1a peptide | 18 Years - 120 Years | Mayo Clinic | |
| Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma | NCT01018004 | Melanoma (Skin) | follow-up care questionnaire a... quality-of-life... | 18 Years - 85 Years | National Cancer Institute (NCI) | |
| Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA Melanoma | NCT00672321 | Melanoma (Skin) | gene expression... mutation analys... polymorphism an... laboratory biom... questionnaire a... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Lovastatin in Treating Patients At High Risk of Melanoma | NCT00462280 | Precancerous Co... Stage 0 Melanom... Stage I Melanom... Stage II Melano... | lovastatin placebo biopsy laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | NCT00118313 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim tetanus toxoid ... dimethyl sulfox... imiquimod adjuvant therap... | 12 Years - 120 Years | University of Virginia | |
| Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | NCT00010309 | Melanoma (Skin) | MART-1 antigen gp100 antigen | 18 Years - | National Cancer Institute (NCI) | |
| Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma | NCT00004153 | Melanoma (Skin) | reverse transcr... sentinel lymph ... | - | University of Chicago | |
| Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma | NCT00002892 | Melanoma (Skin) | recombinant int... | - | National Cancer Institute (NCI) | |
| Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | NCT00861406 | Melanoma | Pegylated Inter... GP-100 Peptide ... | 18 Years - | M.D. Anderson Cancer Center | |
| Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | NCT00470015 | Melanoma (Skin) | MART-1 antigen IL-2 gp100 antigen GM-CSF MART-1a peptide | 18 Years - 120 Years | Mayo Clinic | |
| A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma | NCT05418972 | Stage II Melano... | Relatlimab and ... | 18 Years - | Melanoma Institute Australia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
